Precision Oncology

Oncotype IQ® Portfolio of Tests

Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter at every stage, our Oncotype IQ diagnostic tests and services portfolio delivers clinically relevant genomic intelligence that reveals the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast, colon, and prostate cancers.

In addition to the Oncotype DX suite of tests, the Oncotype IQ portfolio now includes a comprehensive genomic profiling panel to bring fast and informative answers to patients with advanced, metastatic, refractory, or recurrent cancer. The Oncotype MAPTM Pan-Cancer Tissue test provides rapid tumor profiling for advanced cancer patients, giving physicians confidence to deliver fast answers patients need when there is no time to wait. It allows physicians to understand a patient’s tumor profile and recommend targeted therapies or clinical trials, with fast turnaround time1,2 and small samples3.



"With millions of cancer patients around the world, it is critical to be able to individualize care. Oncotype DX tests have paved the way for precision medicine by providing personalized information based on the unique biology of every cancer, and by enabling confident, individualized treatment decisions. Genomic testing has become a mainstream component of cancer care, and patients are seeing the benefits through improved outcomes."

Harold A. Burstein, M.D., Ph.D.Medical Oncologist at the Dana-Farber Cancer Institute

Making Cancer Care Smarter

Oncotype DX for Breast Cancer

Learn more about Oncotype DX tests for DCIS and Early-Stage Breast Cancer

Learn More

Oncotype DX for Prostate Cancer

Learn more about Oncotype DX tests for Early- and Late- Stage Prostate Cancer

Learn More

Oncotype DX for Colon Cancer

Learn more about Oncotype DX test for Colon Cancer

Learn More


Learn more about the Oncotype MAP test for patients with advanced cancer

Learn More

1Data on file, in-house assay optimization protected by trade-secret/patent regulations.

2Turnaround time is based on sample receipt.

3Morris S, Subramanian J, Gel E, Runger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. 10.1371/journal.pone.0196556.